Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
14 NC counties are under alert.
Program
On WRAL at 6 : Unhealthy ingredients in kids' food. 5 On Your Side reveals the findings of a local scientist who researched hundreds of products from local shelves.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Natera Inc
(NQ:
NTRA
)
127.78
+0.65 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,190,370
Open
126.49
Bid (Size)
125.23 (2)
Ask (Size)
128.18 (1)
Prev. Close
127.13
Today's Range
124.79 - 128.40
52wk Range
36.90 - 132.01
Shares Outstanding
123,681,432
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
September 16, 2024
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
September 16, 2024
From
Natera, Inc.
Via
Business Wire
Performance
YTD
+106.36%
+106.36%
1 Month
+4.13%
+4.13%
3 Month
+18.96%
+18.96%
6 Month
+39.82%
+39.82%
1 Year
+182.70%
+182.70%
More News
Read More
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
September 14, 2024
From
Natera, Inc.
Via
Business Wire
Analyst Scoreboard: 9 Ratings For Natera
September 13, 2024
Via
Benzinga
Peering Into Natera's Recent Short Interest
September 06, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Natera Through Analyst Insights
August 27, 2024
Via
Benzinga
Forecasting The Future: 6 Analyst Projections For Natera
August 09, 2024
Via
Benzinga
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
September 08, 2024
From
Natera, Inc.
Via
Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
August 20, 2024
Via
The Motley Fool
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
Via
Benzinga
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
August 06, 2024
Via
Benzinga
(NTRA) - Analyzing Natera's Short Interest
July 23, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
July 18, 2024
Via
Benzinga
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Natera, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
August 08, 2024
Via
Benzinga
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
July 30, 2024
From
Natera, Inc.
Via
Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
July 04, 2024
Via
Benzinga
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
June 20, 2024
Via
Benzinga
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From
Natera, Inc.
Via
Business Wire
The 3 Best Gene Editing Stocks to Buy in July 2024
July 08, 2024
Via
InvestorPlace
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From
Natera, Inc.
Via
Business Wire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Via
Talk Markets
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From
Natera, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.